Brendan Eckelman
Fundador en INHIBRX, INC. .
Fortuna: 80 M $ al 30/04/2024
Cargos activos de Brendan Eckelman
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| INHIBRX, INC. | Fundador | 01/04/2010 | - |
| Director Técnico/Científico/I+D | - | - | |
| Director/Miembro de la Junta | 01/04/2018 | 27/10/2021 |
Historial de carrera de Brendan Eckelman
Antiguos cargos conocidos de Brendan Eckelman.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - | - |
Inhibrx LP
 Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Director de Operaciones | 01/01/2010 | - |
| Fundador | 01/01/2010 | - |
Formación de Brendan Eckelman.
| UC San Diego School of Medicine | Doctorate Degree |
| University of California San Diego | Graduate Degree |
Estadísticas
Internacional
| Estados Unidos | 6 |
Operativa
| Founder | 2 |
| Chief Operating Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| INHIBRX, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Inhibrx LP
Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Health Technology |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
- Bolsa de valores
- Insiders
- Brendan Eckelman
- Experiencia
